A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Exclusion Criteria

• •Draining tunnel count of ≥20 at the Baseline Visit.
• •Surgical or laser intervention for an HS lesion during the Screening Period.
• •Clinical diagnosis of Papillon-Lefèvre Syndrome.
• •Participants with an absolute neutrophil count \<1,000/mm3 at the Screening Visit.
• •Participants having active liver disease or hepatic dysfunction.
• •Have diagnosed periodontal disease under active management by a dentist or expected to have periodontal disease-related procedures within the study period.
• •Received systemic (intravenous or orally \[PO\]) antibiotic therapy within 8 weeks before the Baseline Visit
• •a. Doxycycline or minocycline up to 100 mg twice daily is permitted provided the dosing regimen being stable for at least 8 weeks before the Baseline Visit and is expected to continue.
• •Received PO or transdermal opioid analgesics (except tramadol) for any reason within 4 weeks before the Baseline Visit.
• •Permitted analgesics for HS-related pain have not been at a stable dose regimen for at least 4 weeks before the Baseline Visit.
• •Received prescription topical therapies for the treatment of HS within 2 weeks before the Baseline Visit.
• •Received any anti-tumor necrosis factor (TNF)-α/other biologics treatment within 12 weeks or 5 elimination half-lives, whichever is longer, before the Baseline Visit.
• •Received systemic nonbiologic therapies (eg, corticosteroids and retinoids) for HS within 4 weeks before the Baseline Visit.
• •Received any immunomodulatory agents within 4 weeks before the Baseline Visit.